AN2 Therapeutics, Inc. Stock Research

Market Summary

USD5.71-0.60

Market Closed

-9.51%

ANTX Alerts

1 major insider buys recently.

ANTX Stock Price

ANTX RSI Chart

ANTX Valuation

Market Cap

111.7M

Price/Earnings (Trailing)

-2.73

Price/Sales (Trailing)

82.65

Price/Free Cashflow

-3.34

ANTX Price/Sales (Trailing)

ANTX Profitability

Return on Equity

-36.77%

Return on Assets

-35.29%

Free Cashflow Yield

-29.97%

ANTX Fundamentals

ANTX Revenue

Revenue (TTM)

1.4M

Revenue Y/Y

2.2K%

Revenue Q/Q

35.19%

ANTX Earnings

Earnings (TTM)

-41.0M

Earnings Y/Y

-56.95%

Earnings Q/Q

-4.44%

Price Action

52 Week Range

4.8722.49

(Low)(High)

Last 7 days

-22.3%

Last 30 days

-33.8%

Last 90 days

-53.1%

Trailing 12 Months

-48.7%

ANTX Financial Health

Current Ratio

24.21

ANTX Investor Care

Shares Dilution (1Y)

610.64%

Diluted EPS (TTM)

-2.79

Financials for AN2 Therapeutics

* denotes actual numbers (not divided by Thousands)
Income Statement (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	80.6%	1,351	748	307	94.00	69.00
Operating Expenses	13.1%	42,262	37,380	32,542	27,207	21,574
S&GA Expenses	18.0%	12,751	10,809	9,054	6,317	4,668
R&D Expenses	13.7%	28,511	25,071	22,988	20,140	16,156
Net Income	-11.7%	-40,956	-36,659	-32,263	-27,150	-21,543
Net Income Margin	54.3%	-40.38*	-88.28*	-301.48*	-415*	-
Free Cahsflow	-22.8%	-34,432	-28,037	-23,998	-13,600	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-6.8%	103	110	120	121	65.00
Current Assets	-8.1%	99.00	107	117	120	60.00
Cash Equivalents	-5.5%	27.00	29.00	41.00	83.00	12.00
Liabilities	62.1%	7.00	4.00	4.00	5.00	3.00
Current Liabilities	62.1%	7.00	4.00	4.00	5.00	3.00
Shareholder's Equity	-9.7%	95.00	106	116	115	-47.41
Retained Earnings	-15.2%	-89.72	-77.88	-66.54	-56.42	-47.38
Additional Paid-In Capital	0.8%	185	184	183	172	-
Shares Outstanding	0%	19.00	19.00	19.00	19.00	3.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	3.9%	-33.46	-34.82	-30.02	-25.68	-20.48
Share Based Compensation	31.0%	4.00	3.00	2.00	1.00	1.00
Cashflow From Investing	-0.9%	-21.77	-21.58	-26.25	18.00	-50.02
Cashflow From Financing	1.4%	70.00	69.00	69.00	62.00	79.00

Risks for ANTX

What is the probability of a big loss on ANTX?

85.7%

Probability that AN2 Therapeutics stock will be more than 20% underwater in next one year

85.7%

Probability that AN2 Therapeutics stock will be more than 30% underwater in next one year.

85.7%

Probability that AN2 Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ANTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if AN2 Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for ANTX

Cumulative Returns on ANTX

Which funds bought or sold ANTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-22	American Trust	added	3.27	-34,953	435,440	0.03%
2023-05-22	Arete Wealth Advisors, LLC	added	0.14	-375,148,000	337,000	0.03%
2023-05-22	Raleigh Capital Management Inc.	added	313	198,680	272,190	0.14%
2023-05-22	AMERIPRISE FINANCIAL INC	added	12.92	18,688,300	1,664,420,000	0.55%
2023-05-22	FDx Advisors, Inc.	unchanged	-	-	1,655,000	0.07%
2023-05-22	PUTNAM INVESTMENTS LLC	added	2.62	-37,329,300	428,357,000	0.69%
2023-05-19	Trivant Custom Portfolio Group, LLC	new	-	2,989,680	2,989,680	2.14%
2023-05-19	Coppell Advisory Solutions LLC	sold off	-100	-11,798	-	-%
2023-05-18	COURIER CAPITAL LLC	added	3.57	-20,573	266,690	0.03%
2023-05-18	JPMORGAN CHASE & CO	added	35.87	24,000	84,000	-%

Latest Funds Activity

Are funds buying ANTX calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ANTX

No. of Funds

ANTX Alerts

1 major insider buys recently.

AN2 Therapeutics News

Schedule 13G FIlings of AN2 Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	ra capital management, l.p.	19.5%	3,773,517	SC 13G/A
Feb 14, 2023	citadel advisors llc	6.9%	6	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	4.4%	846,993	SC 13G/A
Feb 13, 2023	pfizer inc	7.02%	0	SC 13G
Feb 13, 2023	brii biosciences ltd	5.4%	1,048,479	SC 13G

ANTX Fair Value

Recent SEC filings of AN2 Therapeutics

View All Filings

Date Filed	Form Type	Document
May 15, 2023	4	Insider Trading
May 11, 2023	10-Q	Quarterly Report
May 11, 2023	8-K	Current Report
Apr 26, 2023	ARS	ARS
Apr 26, 2023	DEF 14A	DEF 14A
Apr 26, 2023	DEFA14A	DEFA14A
Apr 14, 2023	424B5	Prospectus Filed
Apr 13, 2023	EFFECT	EFFECT
Apr 11, 2023	CORRESP	CORRESP
Apr 10, 2023	UPLOAD	UPLOAD

Latest Insider Trading transactions for ANTX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-15	Easom Eric	bought	53,770	5.377	10,000	chief executive officer
2022-11-14	Easom Eric	sold	-345	15.04	-23.00	chief executive officer
2022-11-10	Easom Eric	sold	-67,628	15.3248	-4,413	chief executive officer
2022-11-09	Easom Eric	sold	-157,847	15.6114	-10,111	chief executive officer
2022-11-08	Easom Eric	sold	-109,947	15.5842	-7,055	chief executive officer
2022-11-07	Easom Eric	sold	-195,741	16.0404	-12,203	chief executive officer
2022-11-04	Easom Eric	sold	-139,474	15.7991	-8,828	chief executive officer
2022-11-03	Easom Eric	sold	-223,058	15.7472	-14,165	chief executive officer
2022-11-02	Easom Eric	sold	-23,262	15.0664	-1,544	chief executive officer
2022-10-31	Easom Eric	sold	-41,362	15.3879	-2,688	chief executive officer

About AN2 Therapeutics

Eric Easom

www.an2therapeutics.com/

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

ANTX Income Statement

2023-03-31

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development expense related party	$ 11,985	$ 5,633
General and administrative	4,054	2,050
Total operating expenses	16,039	7,683
Loss from operations	(16,039)	(7,683)
Other income, net	716	28
Net loss	(15,323)	(7,655)
Accretion to redemption value and cumulative dividends on preferred stock		(1,820)
Net loss attributable to common stockholders	$ (15,323)	$ (9,475)
Net loss per share attributable to common stockholders, basic	$ (0.79)	$ (2.98)
Net loss per share attributable to common stockholders, diluted	$ (0.79)	$ (2.98)
Weighted-average number of shares used in computing net loss per share, basic	19,385,646	3,180,717
Weighted-average number of shares used in computing net loss per share, diluted	19,385,646	3,180,717
Other comprehensive loss:
Unrealized gain (loss) on investments	$ 199	$ (131)
Comprehensive loss	$ (15,124)	$ (7,786)

ANTX Balance Sheet

2023-03-31

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 26,709	$ 27,219
Short-term investments	61,806	68,840
Prepaid expenses and other current assets	1,767	2,509
Right-of-use asset, net	34	53
Total current assets	90,316	98,621
Deferred offering costs	48
Long-term investments		3,219
Other assets, long-term	720	720
Total assets	91,084	102,560
Current liabilities:
Accounts payable	3,545	2,122
Accrued compensation	741	2,168
Accrued liabilities	4,241	2,837
Operating lease liabilities	34	53
Options subject to repurchase, short-term	5	6
Total current liabilities	8,566	7,186
Options subject to repurchase, long-term	1	2
Total liabilities	8,567	7,188
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at March 31, 2023 and December 31, 2022; no shares issued and outstanding at March 31, 2023 and December 31, 2022
Common stock, $0.00001 par value; 500,000,000 shares authorized at March 31, 2023 and December 31, 2022; 19,426,452 and 19,402,658 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively
Additional paid-in capital	187,738	185,469
Accumulated other comprehensive loss	(175)	(374)
Accumulated deficit	(105,046)	(89,723)
Total stockholders' equity	82,517	95,372
Total liabilities, redeemable convertible preferred stock, and stockholders' equity	$ 91,084	$ 102,560